10-year outcome for women randomized in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: An anglo-celtic cooperative oncology group study

被引：0

作者：

Stavraka, Chara ^{[1
]}

Evans, T. R. Jeffry ^{[2
]}

Dunlop, Joanna ^{[3
]}

Earl, Helena ^{[4
,5
]}

Cameron, David A. ^{[6
]}

Coleman, Robert E. ^{[7
]}

Perren, Timothy ^{[8
]}

Leonard, Robert C. F. ^{[9
]}

Mansi, Janine L. ^{[1
]}

机构：

[1] Guys & St Thomas NHS Trust, London, England

[2] CR UK Beatson Inst, Inst Canc Sci, Glasqow, Scotland

[3] NHS Natl Serv Scotland, SCTRU, Edinburgh, Midlothian, Scotland

[4] Univ Cambridge, Dept Oncol, Cambridge, England

[5] NIHR Cambridge Biomed Res Ctr, Cambridge, England

[6] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, Canc Edinburgh Res Ctr, Edinburgh, Midlothian, Scotland

[7] Univ Sheffield, Dept Oncol & Metab, Western Bank, Sheffield S10 2TN, S Yorkshire, England

[8] St James Univ Hosp, St Jamess Inst Oncol, Leeds, W Yorkshire, England

[9] Imperial Coll, Hammersmith Campus, Dept Surg & Canc, London, England

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P2-16-15

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2-16-15

引用

页数：2

共 50 条

[1] Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study
Evans, TRJ
Yellowlees, A
Foster, E
Earl, H
Cameron, DA
Hutcheon, AW
Coleman, RE
Perren, T
Gallagher, CJ
Quigley, M
Crown, J
Jones, AL
Highley, M
Robert, LMH
Mansi, JL
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) : 2988 - 2995
[2] Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study
Janine L. Mansi
Ann Yellowlees
Julian Lipscombe
Helena M. Earl
David A. Cameron
Robert E. Coleman
Timothy Perren
Christopher J. Gallagher
Mary Quigley
John Crown
Alison L. Jones
Martin Highley
Robert C. F. Leonard
T. R. Jeffry Evans
[J]. Breast Cancer Research and Treatment, 2010, 122 : 787 - 794
[3] Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study
Mansi, Janine L.
Yellowlees, Ann
Lipscombe, Julian
Earl, Helena M.
Cameron, David A.
Coleman, Robert E.
Perren, Timothy
Gallagher, Christopher J.
Quigley, Mary
Crown, John
Jones, Alison L.
Highley, Martin
Leonard, Robert C. F.
Evans, T. R. Jeffry
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (03) : 787 - 794
[4] 5-year outcome for women randomised in a phase III trial comparing doxorubicin (A) and cyclophosphamide (C) with doxorubicin and docetaxel (D) as primary medical therapy of breast cancer: An Anglo-Celtic Cooperative Oncology Group Study
Evans, T. R.
Yellowlees, A.
Devine, I.
Earl, H. M.
Cameron, D. A.
Hutcheon, A. W.
Coleman, R. E.
Crown, J. P.
Leonard, R. C.
Mansi, J. L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[5] Phase-III trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide for primary breast cancer
Mross, Klaus
[J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (04) : 253 - 254
[6] Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer
Evans, TRJ
Yellowlees, A
Foster, E
Earl, H
Cameron, DA
Hutcheon, AW
Coleman, RE
Crown, J
Leonard, RC
Mansi, JL
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 8S - 8S
[7] Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
Jones, Stephen E.
Savin, Michael A.
Holmes, Frankie Ann
O'Shaughnessy, Joyce A.
Blum, Joanne L.
Vukelja, Svetislava
McIntyre, Kristi J.
Pippen, John E.
Bordelon, James H.
Kirby, Robert
Sandbach, John
Hyman, William J.
Khandelwal, Pankaj
Negron, Angel G.
Richards, Donald A.
Anthony, Stephen P.
Mennel, Robert G.
Boehm, Kristi A.
Meyer, Walter G.
Asmar, Lina
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5381 - 5387
[8] Results of clinical endpoints of a randomized phase It trial with doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer
Schneeweiss, A.
Ruiz, A.
Rovira, P.
Bottini, A.
Manikhas, A.
Wacker, J.
Schumacher, T.
Wolf, M.
Segui, M.
Sinn, P.
Kennedy, L.
Mansouri, K.
Bauknecht, T.
[J]. BREAST, 2009, 18 : S63 - S63
[9] A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer
Lee, Keun Seok
Ro, Jungsil
Nam, Byung-Ho
Lee, Eun Sook
Kwon, Youngmee
Kwon, Hye Soo
Chung, Ki Wook
Kang, Han Sung
Kim, Eun A.
Kim, Seok Won
Shin, Kyung Hwan
Kim, Seok-Ki
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (03) : 481 - 489
[10] A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer
Keun Seok Lee
Jungsil Ro
Byung-Ho Nam
Eun Sook Lee
Youngmee Kwon
Hye Soo Kwon
Ki Wook Chung
Han Sung Kang
Eun A Kim
Seok Won Kim
Kyung Hwan Shin
Seok-Ki Kim
[J]. Breast Cancer Research and Treatment, 2008, 109 : 481 - 489

← 1 2 3 4 5 →